No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of Docmeloxi in subjects with severe renal impairment is not recommended. In patients on hemodialysis, Docmeloxi should not exceed 7.5 mg per day. Docmeloxi is not dialyzable .
Osteoarthritis and Rheumato > The use of Docmeloxi for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Docmeloxi (3.75 mg, 7.5 mg, and 15 mg daily) was compared to placebo. The four primary endpoints were investigator’s global assessment, patient global assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on Docmeloxi 7.5 mg daily and Docmeloxi 15 mg daily showed significant improvement in each of these endpoints compared with placebo.
The use of Docmeloxi for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks’ to 6 months’ duration. In these trials, the efficacy of Docmeloxi, in doses of 7.5 mg/day and 15 mg/day, was comparable to piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial.
The use of Docmeloxi for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Docmeloxi (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving Docmeloxi 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.
Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg Docmeloxi.
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of us e. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and Clinical Trials).
- Docmeloxi is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
NSAIDs, including Docmeloxi tablets, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including Docmeloxi tablets, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Docmeloxi only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2019 Cerner Multum, Inc. Version: 12.03.
Docmeloxi is used to treat tenderness, swelling, and pain caused by the inflammation of osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis in patients 2 years of age or older.
Docmeloxi and ibuprofen belong to the same class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).They are chemically different.Docmeloxi, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs)Ibuprofen is (±) – 2 – (p – isobutylphenyl) propionic acid. What sort of allergic reaction did you have?
when I take advil my lips blow up
Disease-modifying antirheumatic drug
Taking methotrexate with Docmeloxi can increase the levels of methotrexate in your body. This can result in kidney problems and an increased risk of infection.
Generic Name: Docmeloxi (mel OKS i kam)Brand Names: Mobic, Vivlodex, Docmeloxi Comfort Pac
Medically reviewed by Sophia Entringer, PharmD Last updated on Jan 4, 2019.